Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI
Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI
复制标题
DOI：
10.1681/asn.2020060829
复制
发表时间：
2020-11-01
影响因子：
13.6
通讯作者：
Hayek, Salim S.
中科院分区：
文献类型：
--
作者：
Azam, Tariq U.;Shadid, Husam R.;Hayek, Salim S.
阿基通常发生在2019冠状病毒病（COVID-19）患者中。其发病机制知之甚少。尿激酶受体系统是炎症、免疫和凝血之间相互作用的关键调节因子，可溶性尿激酶纤溶酶原激活物受体（suPAR）已被确定为阿基的免疫风险因素。suPAR是否与COVID-19相关的阿基有关尚不清楚。方法在一项针对因COVID-19住院的成人患者的多国观察性研究中，我们测量了352名成人患者的血浆样本中的suPAR水平，这些患者在入院后48小时内收集。我们检查了suPAR水平与住院阿基事件之间的关系。结果在352名患者中（57.4%为男性，13.9%为黑人，平均年龄为61岁），91人（25.9%）在住院期间发生阿基，其中25人（27.4%）需要透析。中位suPAR水平为5.61 ng/ml。阿基发生率随着suPAR三分位数的增加而升高，suPAR 6.86 ng/ml（第三个三分位数）患者的发生率为6.0%。所有suPAR患者
Background AKI commonly occurs in patients with coronavirus disease 2019 (COVID-19). Its pathogenesis is poorly understood. The urokinase receptor system is a key regulator of the intersection between inflammation, immunity, and coagulation, and soluble urokinase plasminogen activator receptor (suPAR) has been identified as an immunologic risk factor for AKI. Whether suPAR is associated with COVID-19-related AKI is unknown.Methods In a multinational observational study of adult patients hospitalized for COVID-19, we measured suPAR levels in plasma samples from 352 adult patients that had been collected within 48 hours of admission. We examined the association between suPAR levels and incident in-hospital AKI.Results Of the 352 patients (57.4% were male, 13.9% were black, and mean age was 61 years), 91 (25.9%) developed AKI during their hospitalization, of whom 25 (27.4%) required dialysis. The median suPAR level was 5.61 ng/ml. AKI incidence rose with increasing suPAR tertiles, from a 6.0% incidence in patients with suPAR 6.86 ng/ml (third tertile). None of the patients with suPAR